Summit Therapeutics
SMMT
14 hedge funds and large institutions have $6.54M invested in Summit Therapeutics in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.62% less ownership
Funds ownership: 4.21% → 3.59% (-0.62%)
14% less capital invested
Capital invested by funds: $7.6M → $6.54M (-$1.06M)
18% less funds holding
Funds holding: 17 → 14 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $51K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$153K |
| 2 |
FFW
Fusion Family Wealth
Woodbury,
New York
|
+$43.8K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$36.1K |
| 4 |
JP Morgan Chase
New York
|
+$34.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.05K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$604K |
| 2 |
First Eagle Investment Management
New York
|
-$478K |
| 3 |
Renaissance Technologies
New York
|
-$164K |
| 4 |
Millennium Management
New York
|
-$126K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$57K |
SMMT Hedge Fund Activity: Q3 2018 in Review
14 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q3 2018, worth a combined $6.54M — down 14% from $7.6M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SMMT and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Acadian Asset Management, adding an estimated $153K. The largest seller was Point72 Asset Management, cutting an estimated $604K.
- 14 institutional investors held Summit Therapeutics (SMMT) as of Q3 2018, down from 17 in Q2 2018.
- Funds reported $6.54M of Summit Therapeutics stock for Q3 2018, down 14% quarter-over-quarter.
- 2 funds opened new Summit Therapeutics positions in Q3 2018 and 5 closed out, a net change of -3 holders.
- The largest Summit Therapeutics buyer in Q3 2018 was Acadian Asset Management, an estimated $153K added.
- The largest Summit Therapeutics seller in Q3 2018 was Point72 Asset Management, an estimated $604K sold.
Based on aggregated 13F filings for Q3 2018.